Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
03 October 2019 | Story Ruan Bruwer | Photo Gallo Images
Lappies Labuschagne
Lappies Labuschagné got his first rugby contract with the Cheetahs after impressing for the Shimlas. He is now playing for Japan – the first Shimla to do so.

Former Shimla Lappies Labuschagné made his ex-coach Jaco Swanepoel proud when he was recently included in the Japan Rugby World Cup (RWC) squad.

Labuschagné, made his debut for Japan on 28 September as captain shortly before the tournament, which is currently under way there, then led Japan to a historic win over Ireland, the world’s fourth-ranked team.


Labuschagné has been playing his rugby in Japan since 2016. Previously, he played for the Shimlas between 2009 and 2012 and captained the team in 2012. At that time, Swanepoel was the head coach of the Shimlas. 

“I’m extremely glad that he got his chance to play in the World Cup, just to prove that he can compete at that level. It was wonderful to see the leadership we knew he had on Saturday,” Swanepoel said.

He believes Labuschagné was unlucky not to have played for the Springboks. In 2013, he was called up to the South African squad, but failed to force his way into the congested Springbok back row. 

“Subjectivity in team selection was the reason that he wasn’t considered. He deserved to be selected and he worked extremely hard. I don’t know of a player who worked harder than him. Nobody wanted to work out with him in the gymnasium, because he always put in extra effort. That made him special.”

Swanepoel describes Labuschagné as a “very special person”.

“Lappies the human being is perhaps a little bit better than Lappies the rugby player.”  

“Hopefully we can get a Japan rugby jersey from him to display in the Shimla room soon,” Swanepoel added.

Labuschagné isn’t the only former Kovsie at the RWC. In the Springbok management team, Rassie Erasmus (head coach), Jacques Nienaber (defence coach), and Vivian Verwant (physiotherapist) are also former Kovsies.


News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept